Raiffeisen Bank International AG Sells 9,670 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Raiffeisen Bank International AG lessened its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 58.0% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 6,989 shares of the medical equipment provider’s stock after selling 9,670 shares during the quarter. Raiffeisen Bank International AG’s holdings in Zimmer Biomet were worth $649,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Alberta Investment Management Corp purchased a new stake in shares of Zimmer Biomet during the second quarter valued at $1,286,000. Creative Planning lifted its holdings in Zimmer Biomet by 24.1% during the 2nd quarter. Creative Planning now owns 31,445 shares of the medical equipment provider’s stock valued at $2,868,000 after buying an additional 6,105 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its holdings in Zimmer Biomet by 6.6% during the 2nd quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 48,523 shares of the medical equipment provider’s stock valued at $4,426,000 after buying an additional 2,997 shares in the last quarter. Sittner & Nelson LLC boosted its position in Zimmer Biomet by 20.8% in the 2nd quarter. Sittner & Nelson LLC now owns 2,575 shares of the medical equipment provider’s stock valued at $235,000 after buying an additional 443 shares during the period. Finally, ABN Amro Investment Solutions bought a new position in Zimmer Biomet in the 2nd quarter worth about $3,181,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on the company. BTIG Research lowered their price target on Zimmer Biomet from $122.00 to $112.00 and set a “buy” rating for the company in a report on Wednesday, November 5th. Raymond James Financial lifted their target price on Zimmer Biomet from $104.00 to $113.00 and gave the company an “outperform” rating in a research report on Friday, August 8th. Royal Bank Of Canada lowered their target price on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Redburn Partners set a $130.00 price target on Zimmer Biomet in a research report on Thursday, September 18th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus target price of $109.00.

Insider Buying and Selling at Zimmer Biomet

In other news, SVP Lori Winkler sold 1,500 shares of Zimmer Biomet stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $104.15, for a total value of $156,225.00. Following the transaction, the senior vice president owned 6,833 shares of the company’s stock, valued at $711,656.95. The trade was a 18.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.39% of the company’s stock.

Zimmer Biomet Stock Up 0.5%

Shares of NYSE ZBH opened at $89.10 on Wednesday. Zimmer Biomet Holdings, Inc. has a 12-month low of $85.33 and a 12-month high of $114.44. The stock’s fifty day simple moving average is $97.95 and its two-hundred day simple moving average is $96.84. The stock has a market capitalization of $17.66 billion, a PE ratio of 21.68, a price-to-earnings-growth ratio of 2.29 and a beta of 0.67. The company has a current ratio of 1.87, a quick ratio of 0.96 and a debt-to-equity ratio of 0.54.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.76% and a net margin of 10.51%.The firm had revenue of $2 billion during the quarter, compared to analyst estimates of $2.01 billion. During the same period in the previous year, the company posted $1.74 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. As a group, analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th were given a dividend of $0.24 per share. This represents a $0.96 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Tuesday, September 30th. Zimmer Biomet’s dividend payout ratio is presently 23.76%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.